EP3341011A4 - Peptidinhibitoren des interleukin-23-rezeptors und deren verwendung zur behandlung entzündlicher erkrankungen - Google Patents

Peptidinhibitoren des interleukin-23-rezeptors und deren verwendung zur behandlung entzündlicher erkrankungen Download PDF

Info

Publication number
EP3341011A4
EP3341011A4 EP16825301.1A EP16825301A EP3341011A4 EP 3341011 A4 EP3341011 A4 EP 3341011A4 EP 16825301 A EP16825301 A EP 16825301A EP 3341011 A4 EP3341011 A4 EP 3341011A4
Authority
EP
European Patent Office
Prior art keywords
peptidinhibitors
interleukin
receptor
treatment
inflammatory diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP16825301.1A
Other languages
English (en)
French (fr)
Other versions
EP3341011A2 (de
Inventor
Ashok Bhandari
Gregory BOURNE
Xiaoli Cheng
Brian Troy FREDERICK
Jie Zhang
Dinesh V. Patel
David Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Protagonist Therapeutics Inc
Original Assignee
Protagonist Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/800,627 external-priority patent/US9624268B2/en
Application filed by Protagonist Therapeutics Inc filed Critical Protagonist Therapeutics Inc
Publication of EP3341011A2 publication Critical patent/EP3341011A2/de
Publication of EP3341011A4 publication Critical patent/EP3341011A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
EP16825301.1A 2015-07-15 2016-07-15 Peptidinhibitoren des interleukin-23-rezeptors und deren verwendung zur behandlung entzündlicher erkrankungen Withdrawn EP3341011A4 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US14/800,627 US9624268B2 (en) 2014-07-17 2015-07-15 Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
PCT/US2015/040658 WO2016011208A1 (en) 2014-07-17 2015-07-15 Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
US201562264820P 2015-12-08 2015-12-08
US201662281123P 2016-01-20 2016-01-20
PCT/US2016/042680 WO2017011820A2 (en) 2015-07-15 2016-07-15 Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases

Publications (2)

Publication Number Publication Date
EP3341011A2 EP3341011A2 (de) 2018-07-04
EP3341011A4 true EP3341011A4 (de) 2019-02-20

Family

ID=57757647

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16825301.1A Withdrawn EP3341011A4 (de) 2015-07-15 2016-07-15 Peptidinhibitoren des interleukin-23-rezeptors und deren verwendung zur behandlung entzündlicher erkrankungen

Country Status (23)

Country Link
EP (1) EP3341011A4 (de)
JP (1) JP6858174B2 (de)
KR (1) KR102513978B1 (de)
CN (1) CN108348580B (de)
AU (1) AU2016293619B2 (de)
BR (1) BR112018000691A2 (de)
CA (1) CA2991984A1 (de)
CL (3) CL2018000128A1 (de)
CO (1) CO2018000349A2 (de)
CR (1) CR20180029A (de)
DO (1) DOP2018000010A (de)
EA (1) EA035733B9 (de)
EC (1) ECSP18002929A (de)
HK (1) HK1257747A1 (de)
IL (1) IL256827A (de)
MX (1) MX384213B (de)
NI (1) NI201800008A (de)
PE (1) PE20180571A1 (de)
PH (1) PH12018500086A1 (de)
SG (1) SG10201912066SA (de)
SV (1) SV2018005614A (de)
UA (1) UA123772C2 (de)
WO (1) WO2017011820A2 (de)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS58514B1 (sr) 2012-06-13 2019-04-30 Incyte Holdings Corp Supstituisana triciklična jedinjenja kao inhibitori fgfr
EP4091624A1 (de) 2013-03-15 2022-11-23 Protagonist Therapeutics, Inc. Hepcidin-analoga und verwendungen davon
PH12015502383B1 (en) 2013-04-19 2023-02-03 Incyte Holdings Corp Bicyclic heterocycles as fgfr inhibitors
HRP20211448T1 (hr) 2014-05-16 2021-12-24 Protagonist Therapeutics, Inc. Alfa4beta7 integrin tioeter peptidni antagonisti
CN107206254B (zh) 2014-07-17 2021-08-24 领导医疗有限公司 白细胞介素-23受体的口服肽抑制剂以及其治疗炎症性肠病的用途
WO2016054411A1 (en) 2014-10-01 2016-04-07 Protagonist Therapeutics, Inc. NOVEL α4β7 PEPTIDE MONOMER AND DIMER ANTAGONISTS
US10301371B2 (en) 2014-10-01 2019-05-28 Protagonist Therapeutics, Inc. Cyclic monomer and dimer peptides having integrin antagonist activity
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
TWI712601B (zh) 2015-02-20 2020-12-11 美商英塞特公司 作為fgfr抑制劑之雙環雜環
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
US10787490B2 (en) 2015-07-15 2020-09-29 Protaganist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
GB2545898B (en) 2015-12-21 2019-10-09 Sutura Therapeutics Ltd Improved drug delivery by conjugating oligonucleotides to stitched/stapled peptides
US20190002503A1 (en) 2015-12-30 2019-01-03 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
CA3017926C (en) 2016-03-23 2023-10-10 Protagonist Therapeutics, Inc. Methods for synthesizing .alpha.4.beta.7 peptide antagonists
WO2018136646A1 (en) 2017-01-18 2018-07-26 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
GB2563875B (en) * 2017-06-28 2020-08-19 Sutura Therapeutics Ltd Improvements in drug delivery
EP3681900A4 (de) 2017-09-11 2021-09-08 Protagonist Therapeutics, Inc. Opioidagonistpeptide und verwendungen davon
CA3089868A1 (en) 2018-02-08 2019-08-15 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
HRP20241288T1 (hr) 2018-05-04 2024-12-06 Incyte Corporation Čvrsti oblici fgfr inhibitora i postupci za njihovu proizvodnju
AU2019262579B2 (en) 2018-05-04 2024-09-12 Incyte Corporation Salts of an FGFR inhibitor
WO2020014646A1 (en) * 2018-07-12 2020-01-16 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
CN110015978B (zh) * 2019-04-29 2021-03-19 康化（上海）新药研发有限公司 O-[2-[[叔丁氧羰基]氨基]乙基]-n-[芴甲氧羰基]-l-酪氨酸的合成方法
US20220251185A1 (en) * 2019-07-01 2022-08-11 Valitor, Inc. Hydrophilic linkers for multivalent peptide conjugates
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
JP7534382B2 (ja) * 2019-07-10 2024-08-14 プロタゴニスト セラピューティクス， インコーポレイテッド インターロイキン－２３受容体のペプチド阻害剤及び炎症性疾患を治療するためのその使用
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CA3157361A1 (en) 2019-10-14 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
EP3819307A1 (de) * 2019-11-07 2021-05-12 CytoKi Pharma ApS Therapeutische derivate von interleukin-22
JP7832891B2 (ja) 2019-12-04 2026-03-18 インサイト・コーポレイション Ｆｇｆｒ阻害剤の誘導体
CA3163875A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
CA3167751A1 (en) 2020-01-15 2021-07-22 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
AU2021209086A1 (en) * 2020-01-15 2022-08-04 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
AU2021301192A1 (en) * 2020-06-29 2023-02-02 University Of Washington Human IL23 receptor binding polypeptides
JP2023542867A (ja) 2020-09-11 2023-10-12 グリンプス バイオ， インコーポレイテッド 疾患の検出／診断、病期分類、モニタリング及び処置のための生体外でのプロテアーゼ活性検出
JP7397239B2 (ja) 2020-11-20 2023-12-12 ヤンセン ファーマシューティカ エヌ．ベー． インターロイキン－２３受容体のペプチド阻害剤の組成物
JP2023145581A (ja) * 2020-11-20 2023-10-11 ヤンセン ファーマシューティカ エヌ．ベー． インターロイキン－２３受容体のペプチド阻害剤の組成物
WO2022221170A1 (en) 2021-04-12 2022-10-20 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
US11939331B2 (en) 2021-06-09 2024-03-26 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
CA3220155A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
EP4370146A4 (de) 2021-07-14 2025-05-21 Janssen Biotech, Inc. Lipidierte peptidinhibitoren des interleukin-23-rezeptors
TW202332683A (zh) * 2021-07-14 2023-08-16 美商健生生物科技公司 介白素－２３受體之肽抑制劑
EP4370532A4 (de) * 2021-07-14 2025-09-03 Janssen Biotech Inc Bicyclische peptidinhibitoren des interleukin-23-rezeptors
AU2022402440A1 (en) 2021-12-01 2024-05-30 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor
WO2023172648A2 (en) * 2022-03-09 2023-09-14 Glympse Bio, Inc. Fluorogenic substrates for aminopeptidase detection in biofluids
CN114751962B (zh) * 2022-03-17 2023-11-07 北京大学 订书肽、其制备方法及其制药用途
CA3260606A1 (en) 2022-06-30 2024-01-04 Sanofi NEW PEPTIDES FOR USE AS SELECTIVE IL-23 RECEPTOR ANTAGONISTS
WO2024110477A2 (en) * 2022-11-21 2024-05-30 Janssen Pharmaceutica Nv Synthesis of a cyclic peptide
US20240279281A1 (en) * 2023-01-16 2024-08-22 Janssen Pharmaceutica Nv Peptide Inhibitors of Interleukin-23 Receptor
EP4652180A2 (de) * 2023-01-16 2025-11-26 Janssen Pharmaceutica NV Peptidinhibitoren des interleukin-23-rezeptors
WO2024155551A1 (en) * 2023-01-16 2024-07-25 Janssen Pharmaceutica Nv Polycyclic peptide inhibitors of interleukin-23 receptor
IL322423A (en) 2023-01-31 2025-09-01 Janssen Pharmaceutica Nv Methods for preparing crystalline peptide inhibitors of the interleukin-23 receptor
CN121443624A (zh) * 2023-05-04 2026-01-30 西藏海思科制药有限公司 白介素-23受体的肽抑制剂制备及其用途
EP4471049A1 (de) 2023-06-01 2024-12-04 Zealand Pharma A/S Peptidinhibitoren des interleukin-23-rezeptors
EP4471048A1 (de) 2023-06-01 2024-12-04 Zealand Pharma A/S Peptidinhibitoren des interleukin-23-rezeptors
CN121794283A (zh) 2023-09-08 2026-04-03 赛诺菲 作为选择性il-23受体抑制剂的新型肽
CN121909205A (zh) 2023-09-08 2026-04-21 赛诺菲 作为选择性il-23受体抑制剂的新型肽
WO2026013260A1 (en) 2024-07-12 2026-01-15 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor
WO2026057052A1 (zh) * 2024-09-14 2026-03-19 深圳信立泰药业股份有限公司 一种il-23受体抑制剂及其制备方法和用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130183755A1 (en) * 2010-03-31 2013-07-18 Grant Gallagher Therapeutic application of isolated naturally-occurring soluble truncated forms of il-23 receptor
WO2016011208A1 (en) * 2014-07-17 2016-01-21 Protagonist Therapeutics, Inc. Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5942492A (en) * 1996-11-12 1999-08-24 Angstrom Pharmaceuticals, Inc. Cyclic peptides that bind to urokinase-type plasminogen activator receptor
CA2677932A1 (en) 2007-02-15 2008-08-21 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
JP2011501941A (ja) * 2007-07-06 2011-01-20 バロリゼイション エイチエスジェイ， ソシエテ アン コマンディテ Ｉｌ−２３レセプターのアンタゴニストおよびその使用
CA2707840A1 (en) 2007-08-20 2009-02-26 Allozyne, Inc. Amino acid substituted molecules
US8946150B2 (en) * 2011-06-14 2015-02-03 Medical Diagnostic Laboratories, LLC. Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof
US9169292B2 (en) * 2011-06-14 2015-10-27 Medical Diagnostic Laboratories, Llc Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof
US20160235807A1 (en) * 2013-10-09 2016-08-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for downregulation of pro-inflammatory cytokines

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130183755A1 (en) * 2010-03-31 2013-07-18 Grant Gallagher Therapeutic application of isolated naturally-occurring soluble truncated forms of il-23 receptor
WO2016011208A1 (en) * 2014-07-17 2016-01-21 Protagonist Therapeutics, Inc. Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2017011820A2 *

Also Published As

Publication number Publication date
CL2021000343A1 (es) 2021-08-06
CO2018000349A2 (es) 2018-07-10
HK1259149A1 (zh) 2019-11-29
IL256827A (en) 2018-03-29
HK1257747A1 (zh) 2019-10-25
ECSP18002929A (es) 2018-03-31
UA123772C2 (uk) 2021-06-02
JP2018522008A (ja) 2018-08-09
WO2017011820A3 (en) 2017-02-23
KR20180030663A (ko) 2018-03-23
AU2016293619A1 (en) 2018-02-01
DOP2018000010A (es) 2018-03-30
MX2018000542A (es) 2018-06-27
MX384213B (es) 2025-03-14
NI201800008A (es) 2018-06-29
CN108348580B (zh) 2022-05-10
EA035733B9 (ru) 2021-01-14
EA201890325A1 (ru) 2018-06-29
SG10201912066SA (en) 2020-02-27
CA2991984A1 (en) 2017-01-19
CN108348580A (zh) 2018-07-31
JP6858174B2 (ja) 2021-04-14
EA035733B1 (ru) 2020-07-31
AU2016293619B2 (en) 2021-02-25
CL2018000128A1 (es) 2018-06-15
EP3341011A2 (de) 2018-07-04
CL2018003322A1 (es) 2019-01-18
BR112018000691A2 (pt) 2018-09-18
CR20180029A (es) 2018-06-05
WO2017011820A2 (en) 2017-01-19
PE20180571A1 (es) 2018-04-04
SV2018005614A (es) 2018-05-22
PH12018500086A1 (en) 2018-07-30
KR102513978B1 (ko) 2023-03-27

Similar Documents

Publication Publication Date Title
EP3341011A4 (de) Peptidinhibitoren des interleukin-23-rezeptors und deren verwendung zur behandlung entzündlicher erkrankungen
EP3570864C0 (de) Peptidinhibitoren des interleukin-23-rezeptors und deren verwendung zur behandlung entzündlicher erkrankungen
EP3820883A4 (de) Peptidinhibitoren des interleukin-23-rezeptors und deren verwendung zur behandlung entzündlicher erkrankungen
EP3359171C0 (de) Verwendung von akkermansia muciniphila zur behandlung von entzündlichen erkrankungen
EP3383411C0 (de) Sub-mitochondrielle partikel zur verwendung bei der behandlung metabolischer erkrankungen
EP3263132C0 (de) Zusammensetzung zur behandlung von il-6-assoziierten erkrankungen
EP3919049C0 (de) Kombinationen aus rapamycin und metformin zur behandlung von gelenk- und hautkrankheiten
IL255109A0 (en) New dihydropyridoisoquinolinones and their pharmaceutical preparations for the treatment of inflammatory disorders
ZA202002166B (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
EP3795148C0 (de) Verwendung von agonisten des formylpeptidrezeptors 2 zur behandlung von augenentzündungen
IL269158A (en) Compositions and methods for treating inflammatory diseases
GB201411241D0 (en) Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders
EP3689875A4 (de) Verwendung von triazolopyrimidin-, triazolopyridinverbindungen und zusammensetzung davon zur behandlung von prc2-vermittelten erkrankungen
EP3582768A4 (de) Formulierungen von cannabinoiden zur behandlung von dermatitis und entzündlichen hauterkrankungen
GB201401086D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
EP3398437A4 (de) Metconazohaltige pestizidzusammensetzung zur vorbeugung und behandlung von ährenfusariosen und verwendung davon
EP3823928C0 (de) Graphenprodukt und therapeutische verwendung davon
EP3583113A4 (de) Verwendung von tgf-alpha zur behandlung von krankheiten und störungen
EP3185862A4 (de) Schützende metallothioneinanalogverbindungen, deren zusammensetzungen und verwendung davon bei der behandlung von pathogenen erkrankungen
EP3395341C0 (de) Zusammensetzung zur behandlung von motoneuronenerkrankungen und verwendung davon
IL260987A (en) Treatment and diagnosis of inflammatory disorders
EP3654961C0 (de) Zusammensetzungen und ihre verwendung zur behandlung von schmerzen mit capsaicin
EP3558335A4 (de) Caspase-1-inhibition und deren verwendung zur vorbeugung und behandlung von neurologischen erkrankungen
EP3488850A4 (de) Neuartige verwendung von gzd824 und pharmazeutisch akzeptable salze davon zur behandlung von krankheiten
EP3262065C0 (de) Verfahren und zusammensetzungen zur behandlung von dystroglycanopathieerkrankungen

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20180212

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20190121

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 7/08 20060101ALI20190115BHEP

Ipc: A61K 38/20 20060101AFI20190115BHEP

Ipc: C07K 14/54 20060101ALI20190115BHEP

Ipc: C07K 7/06 20060101ALI20190115BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1257747

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20200213

RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: PROTAGONIST THERAPEUTICS, INC.

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230515

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0038200000

Ipc: C07K0007060000

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 38/00 20060101ALN20240724BHEP

Ipc: A61P 37/06 20060101ALI20240724BHEP

Ipc: A61P 37/02 20060101ALI20240724BHEP

Ipc: A61P 35/00 20060101ALI20240724BHEP

Ipc: A61P 29/00 20060101ALI20240724BHEP

Ipc: A61P 19/02 20060101ALI20240724BHEP

Ipc: A61P 17/06 20060101ALI20240724BHEP

Ipc: A61P 15/00 20060101ALI20240724BHEP

Ipc: A61P 11/06 20060101ALI20240724BHEP

Ipc: A61P 11/02 20060101ALI20240724BHEP

Ipc: A61P 7/00 20060101ALI20240724BHEP

Ipc: A61P 3/10 20060101ALI20240724BHEP

Ipc: A61P 3/00 20060101ALI20240724BHEP

Ipc: A61P 1/18 20060101ALI20240724BHEP

Ipc: A61P 1/16 20060101ALI20240724BHEP

Ipc: A61P 1/04 20060101ALI20240724BHEP

Ipc: C07K 7/08 20060101ALI20240724BHEP

Ipc: C07K 7/06 20060101AFI20240724BHEP

INTG Intention to grant announced

Effective date: 20240806

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTC Intention to grant announced (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 38/00 20060101ALN20241125BHEP

Ipc: A61P 37/06 20060101ALI20241125BHEP

Ipc: A61P 37/02 20060101ALI20241125BHEP

Ipc: A61P 35/00 20060101ALI20241125BHEP

Ipc: A61P 29/00 20060101ALI20241125BHEP

Ipc: A61P 19/02 20060101ALI20241125BHEP

Ipc: A61P 17/06 20060101ALI20241125BHEP

Ipc: A61P 15/00 20060101ALI20241125BHEP

Ipc: A61P 11/06 20060101ALI20241125BHEP

Ipc: A61P 11/02 20060101ALI20241125BHEP

Ipc: A61P 7/00 20060101ALI20241125BHEP

Ipc: A61P 3/10 20060101ALI20241125BHEP

Ipc: A61P 3/00 20060101ALI20241125BHEP

Ipc: A61P 1/18 20060101ALI20241125BHEP

Ipc: A61P 1/16 20060101ALI20241125BHEP

Ipc: A61P 1/04 20060101ALI20241125BHEP

Ipc: C07K 7/08 20060101ALI20241125BHEP

Ipc: C07K 7/06 20060101AFI20241125BHEP

INTG Intention to grant announced

Effective date: 20241218

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20250423

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1257747

Country of ref document: HK